Daiichi Sankyo Nordics ApS: Financial statements 2021
CVR: 39371049
Source: annual report 2021, Danish Business Authority
01/04/2020 – 31/03/2021
Daiichi Sankyo Nordics ApS (CVR 39371049) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK 27,406,905 and a net result of DKK 846,325 compared with DKK 1,187,436 the year before. That is an increase of 33% compared with the year before. Equity in the 2021 report amounted to DKK 3,336,942. The solvency ratio was 16.9%. The company had 16 employees in the financial year.
- Gross Profit
- DKK 27,406,905
- Profit/Loss
- DKK 846,325
- Equity
- DKK 3,336,942
- Total Assets
- DKK 19,754,804
- Employees
- 16
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | 27.4M | 846K | 3.3M | 16 |
| 2020 | - | 20.6M | 1.2M | 2.5M | 16 |
| 2019 | - | 2.9M | 253K | 1.3M | 2 |
Official annual report
Find more companies like Daiichi Sankyo Nordics ApS
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorAbout Daiichi Sankyo Nordics ApS
Daiichi Sankyo Nordics ApS is a Danish company of the type Anpartsselskab based in København S, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Daiichi Sankyo Oncology Nordics ApS. The management consists of Christophe Tiberghien. The board consists of Christophe Tiberghien, Jacob Wessel-Tolvig and Karin Margaretha Heisterberg. The company is owned by Daiichi Sankyo Oncology Europe GmbH. The company has 32 employees (2026). In 2026, the company reported a gross profit of DKK 83,558,930 and a net result of DKK 17,269,490 compared with DKK 9,020,707 the year before. Equity in the 2026 report amounted to DKK 40,346,412.
